Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up.

Guideline ID: 1931 Published: 2022 Dec

European Society for Medical Oncology (ESMO)

Haanen J, Obeid M, Spain L, et al. Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022 Dec;33(12):1217-1238. [115 references] PubMed

View Original Guideline

Overview

Guideline Objective

To provide recommendations on diagnosis, treatment, and follow-up of immune-related adverse events (irAEs)

Patient Population

Patients with suspected or confirmed toxicities from immunotherapy

Recommendations

Recommendation Statements

Major interventions covered in this guideline include:

- Diagnostic tests and pharmacological management based on toxicity type, including skin, endocrinopathies, hepatotoxicity, cholangitis, pancreatic, gastrointestinal, pulmonary, rheumatological, neurological, cardiovascular, renal, ocular, and haematological
- Continuation or discontinuation of immunotherapy
- Considerations for hospital admission or specialist referral

Note: Full recommendation statements have not been provided because this guideline does not meet EGT's systematic review of the evidence criteria. Refer to the original guideline for more information.

Evidence Rating Scheme

Refer to the original guideline documentation for more information.

Recommendation Rating Scheme

Refer to the original guideline documentation for more information.

Related Content

Supporting Documents

- Supplementary Material.
- ESMO Standard Operating Procedures (SOPs) for Clinical Practice Guidelines.

Implementation Tools

- ESMO Pocket Guidelines & Mobile App.

Patient Education

No patient education materials available.

Disclaimer

If you desire to use content from the original clinical practice guideline cited herein, you must contact the guideline developer directly to obtain permission rights.

ECRI's Guideline Profiles are designed to provide information and assist decision-making. Variations in practice will inevitably, and appropriately, occur when clinicians take into account the needs and preferences of individual patients, available resources, and limitations unique to an institution or type of practice. Every healthcare professional using these Guideline Profiles is responsible for evaluating the appropriateness of applying them in a clinical setting.

Copyright © 2025 ECRI